Export 549 results:
[ Author(Desc)] Title Type Year
Filters: Keyword is Alzheimer Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A. Hatami, Monjazeb, S., and Glabe, C., The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils., J Alzheimers Dis, vol. 50, no. 2, pp. 517-25, 2016.
S. Hatashita and Wakebe, D., Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging., J Alzheimers Dis, vol. 57, no. 3, pp. 765-773, 2017.
G. He, Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P., and Greengard, P., Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease., Nature, vol. 467, no. 7311, pp. 95-8, 2010.
X. - Y. He, Isaacs, C., and Yang, S. - Y., Roles of Mitochondrial 17β-Hydroxysteroid Dehydrogenase Type 10 in Alzheimer's Disease., J Alzheimers Dis, vol. 62, no. 2, pp. 665-673, 2018.
E. Healy, Impact of the MIND Diet on Cognition in Individuals with Dementia., J Alzheimers Dis, vol. 96, no. 3, pp. 967-977, 2023.
J. Heinrich, Vidal, J. - S., Simon, A., Rigaud, A. - S., Hanon, O., Epelbaum, J., Viollet, C., and Duron, E., Relationships Between Lower Olfaction and Brain White Matter Lesions in Elderly Subjects with Mild Cognitive Impairment., J Alzheimers Dis, vol. 61, no. 3, pp. 1133-1141, 2018.
K. Hensley and Kursula, P., Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau., J Alzheimers Dis, vol. 53, no. 1, pp. 1-14, 2016.
P. Heßmann, Seeberg, G., Reese, J. Peter, Dams, J., Baum, E., Müller, M. J., Dodel, R., and Balzer-Geldsetzer, M., Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings., J Alzheimers Dis, vol. 51, no. 2, pp. 545-61, 2016.
H. Hochstetler, Trzepacz, P. T., Wang, S., Yu, P., Case, M., Henley, D. B., Degenhardt, E., Leoutsakos, J. - M., and Lyketsos, C. G., Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline., J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
K. Hoffmann, Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., Brændgaard, H., Gottrup, H., Lolk, A., Wermuth, L., Jacobsen, S., Laugesen, L. P., Gergelyffy, R. G., Høgh, P., Bjerregaard, E., Andersen, B. B., Siersma, V., Johannsen, P., Cotman, C. W., Waldemar, G., and Hasselbalch, S. G., Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial., J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
A. Homma, Atarashi, H., Kubota, N., Nakai, K., and Takase, T., Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial., J Alzheimers Dis, vol. 52, no. 1, pp. 345-57, 2016.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial., J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
L. Huang, Lu, Z., Zhang, H., Wen, H., Li, Z., Liu, Q., and Wang, R., A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora., J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
W. Huang, Xia, Q., Zheng, F., Zhao, X., Ge, F., Xiao, J., Liu, Z., Shen, Y., Ye, K., Wang, D., and Li, Y., Microglia-Mediated Neurovascular Unit Dysfunction in Alzheimer's Disease., J Alzheimers Dis, vol. 94, no. s1, pp. S335-S354, 2023.
F. Huang, Shang, Y., Luo, Y., Wu, P., Huang, X., Tan, X., Lu, X., Zhen, L., and Hu, X., Lower Prevalence of Alzheimer's Disease among Tibetans: Association with Religious and Genetic Factors., J Alzheimers Dis, vol. 50, no. 3, pp. 659-67, 2016.
S. - Y. Huang, Yang, Y. - X., Zhang, Y. - R., Kuo, K., Li, H. - Q., Shen, X. - N., Chen, S. - D., Chen, K. - L., Dong, Q., Tan, L., and Yu, J. - T., Investigating Causal Relations Between Circulating Metabolites and Alzheimer's Disease: A Mendelian Randomization Study., J Alzheimers Dis, vol. 87, no. 1, pp. 463-477, 2022.
C. M. Huber, Yee, C., May, T., Dhanala, A., and Mitchell, C. S., Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy., J Alzheimers Dis, vol. 61, no. 1, pp. 265-281, 2018.
H. Y. H. Hui, Ran, A. Ran, Dai, J. Jia, and Cheung, C. Y., Deep Reinforcement Learning-Based Retinal Imaging in Alzheimer's Disease: Potential and Perspectives., J Alzheimers Dis, vol. 94, no. 1, pp. 39-50, 2023.
B. T. Hyman, Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., Nelson, P. T., Schneider, J. A., Thal, D. Rudolf, Thies, B., Trojanowski, J. Q., Vinters, H. V., and Montine, T. J., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease., Alzheimers Dement, vol. 8, no. 1, pp. 1-13, 2012.
R. Iban-Arias, Trageser, K. J., Yang, E. - J., Griggs, E., Radu, A., Naughton, S., Rahim, M. Al, Tatsunori, O., Raval, U., Palmieri, J., Huang, Z., Chen, L. - C., and Pasinetti, G. Maria, Exposure to World Trade Center Dust Exacerbates Cognitive Impairment and Evokes a Central and Peripheral Pro-Inflammatory Transcriptional Profile in an Animal Model of Alzheimer's Disease., J Alzheimers Dis, vol. 91, no. 2, pp. 779-794, 2023.
M. Ibarria, Alegret, M., Valero, S., Morera, A., Guitart, M., Cañabate, P., Moreno, M., Lara, S., Diego, S., Hernández, J., Tantinyá, N., Vera, M., Hernandez, I., Becker, J. T., Ruiz, A., Boada, M., and Tárraga, L., Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease., J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.
S. Ikeda, Mimura, M., Ikeda, M., Wada-Isoe, K., Azuma, M., Inoue, S., and Tomita, K., Economic Burden of Alzheimer's Disease Dementia in Japan., J Alzheimers Dis, vol. 81, no. 1, pp. 309-319, 2021.
A. Imai, Matsuoka, T., and Narumoto, J., Emotional Dysregulation in Mild Behavioral Impairment Is Associated with Reduced Cortical Thickness in the Right Supramarginal Gyrus., J Alzheimers Dis, vol. 93, no. 2, pp. 521-532, 2023.
K. K. Indorewalla, O'Connor, M. K., Budson, A. E., DiTerlizzi, C. Guess, and Jackson, J., Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer's Disease Research., J Alzheimers Dis, vol. 80, no. 3, pp. 927-940, 2021.
K. Iqbal, Liu, F., Gong, C. - X., and Grundke-Iqbal, I., Tau in Alzheimer disease and related tauopathies., Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.